ClinicalTrials.gg
CompletedNCT01970215TULIPUpdated Aug 21, 2014

TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

A Phase 2 interventional study of TA-8995 and Atorvastatin in Dyslipidemia, sponsored by Xention Ltd. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-21.

Sponsored by Xention Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.

Enrollment
3rd of 14
364 · median 116
Started
2013
the only one that year
Phase 2
6 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
4 of 14
Xention Ltd

Among the 14 studies testing TA-8995 in Dyslipidemias, this one is the 3rd largest by enrollment, is the only one that started in 2013, is one of 6 in phase 2, and was the 3rd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About TA-8995

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing TA-8995 in Dyslipidemias, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of different doses of TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy.

The secondary objectives of this study are to determine the safety and tolerability of TA-8995 in patients with mild dyslipidaemia.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-C levels >2.5 mmol/L and \<4.5 mmol/L, HDL-C levels \<1.8 mmol/L and >0.8 mmol/L, and TG levels \<4.5 mmol/L after run in or washout of existing therapies
  • Not on lipid-altering therapy at screening or on lipid-altering treatment regimens at screening

Exclusion criteria

Exclusion Criteria:

  • >32 kg/m2;
  • Participation in another clinical study involving an or marketed drug within 30 days prior to enrolment (Visit 2);
  • Any clinical manifestation of atherosclerotic vascular disease;
  • Diagnosis of type 1 diabetes;
  • Uncontrolled type 2 diabetes: >8%;
  • Uncontrolled hypertension: sitting systolic blood pressure >160 mmHg and/or sitting diastolic blood pressure >90 mmHg;
  • History of hyperaldosteronism;
  • Active muscle disease or persistent creatine kinase concentration >3 × the (ULN). One retest will be allowed after 1 week to verify the result;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
364 participants (actual)

Study arms

  • Placebo comparator
    Group 1

    TA-8995 0mg (placebo) \& placebo statin

    Drug: TA-8995 0mg (placebo) · Drug: Placebo Statin

  • Experimental
    Group 2

    TA-8995 1mg \& placebo statin

    Drug: TA-8995 · Drug: Placebo Statin

  • Experimental
    Group 3

    TA-8995 2.5mg \& placebo statin

    Drug: TA-8995 · Drug: Placebo Statin

  • Experimental
    Group 4

    TA-8995 5mg \& placebo statin

    Drug: TA-8995 · Drug: Placebo Statin

  • Experimental
    Group 5

    TA-8995 10mg \& placebo statin

    Drug: TA-8995 · Drug: Placebo Statin

  • Active comparator
    Group 6

    TA-8995 0mg (placebo) \& atorvastatin 20mg

    Drug: Atorvastatin · Drug: TA-8995 0mg (placebo)

  • Active comparator
    Group 7

    TA-8995 10mg \& atorvastatin 20mg

    Drug: TA-8995 · Drug: Atorvastatin

  • Active comparator
    Group 8

    TA-8995 0mg (placebo) \& rosuvastatin 10mg

    Drug: Rosuvastatin · Drug: TA-8995 0mg (placebo)

  • Active comparator
    Group 9

    TA-8995 10mg \& rosuvastatin 10mg

    Drug: TA-8995 · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. The co-primary efficacy endpoints are the percentage changes in both HDL-C and LDL-C levels at Week 12 compared to baseline.

    Time frame: 12 weeks

07

Study locations

17 sites
  • H:S Amager Hospital
    Copenhagen, Denmark
  • Sydvestjysk Sygehus
    Esbjerg, Denmark
  • Herlev University Hospital
    Herlev, Denmark
  • Hvidovre Hospital
    Hvidovre, Denmark
  • Regionshopitalet - Silkeborg
    Silkeborg, Denmark
  • EB FlevoResearch B.V
    Almere, Netherlands
  • Academic Medical Centre
    Amsterdam-Zuidoost, Netherlands
  • Andromed Amsterdam
    Amsterdam, Netherlands
  • Andromed Leiden
    Amsterdam, Netherlands
  • Andromed Breda B.V
    Breda, Netherlands
  • Andromed Eindhoven
    Eindhoven, Netherlands
  • Andromed Noord B.V
    Groningen, Netherlands
  • Andromed Zoetermeer
    Leiderdorp, Netherlands
  • Andromed Rotterdam BV
    Rotterdam, Netherlands
  • Albert Schweitzer Ziekenhuis
    Sliedrecht, Netherlands
  • Andromed Oost
    Velp, Netherlands
  • Praktijk Zwijndrecht
    Zwijndrecht, Netherlands
08

References and documents

Publications

  • van Capelleveen JC, Kastelein JJ, Zwinderman AH, van Deventer SJ, Collins HL, Adelman SJ, Round P, Ford J, Rader DJ, Hovingh GK. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. J Clin Lipidol. 2016 Sep-Oct;10(5):1137-1144.e3. doi: 10.1016/j.jacl.2016.06.006. Epub 2016 Jun 25. PubMed 27678430 ↗
  • Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015 Aug 1;386(9992):452-60. doi: 10.1016/S0140-6736(15)60158-1. Epub 2015 Jun 2. PubMed 26047975 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2013
First posted
Oct 28, 2013
Start
Aug 2013
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Aug 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01970215
Lead sponsor
Xention Ltd
Responsible party
Sponsor
First posted
Oct 28, 2013
Start date
Aug 2013
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Aug 21, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion